Oppenheimer raised the firm’s price target on Avadel Pharmaceuticals to $25 from $22 and keeps an Outperform rating on the shares. The firm came away from the company’s commercial day “impressed” by Lumryz’s early commercial signals. The firm is “pleased” to see Avadel making “great strides” with earlier than anticipated reimbursement wins.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AVDL:
- Avadel Pharmaceuticals to Host Commercial Day on June 29 for LUMRYZ™ (sodium oxybate) extended release for oral solution, CIII
- Avadel Pharmaceuticals sponsors AASM Foundation’s 2023 YIRF
- Avadel Pharmaceuticals Sponsors the Academy of Sleep Medicine Foundation’s 2023 Young Investigators Research Forum
- Avadel Pharmaceuticals announces publication of survey data on oxybate
- Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)